Lower respiratory tract Microbiome in patients with Lung cancer (LML)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025048

Enrollment

150

Registered

2021-10-13

Start date

2021-09-07

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34 J44.9

Interventions

Group 1: suspected or proven lung cancer (study group) Group 2: COPD (control group)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with a) suspected or proven lung cancer (study group) or b) COPD (control group) 2. scheduled for bronchoscopy and/or surgical resection at the Medical Center Freiburg 3. Male and female patients, = 18 years of age

Exclusion criteria

Exclusion criteria: 1. Patients with history of systemic corticosteroids and/or immunosuppressive therapy in the last 12 months before enrolment 2. Patients with history of systemic antibiotics for any reason in the last 4 weeks before enrolment 3. Patients with history of chemotherapy and/or radiation

Design outcomes

Primary

Measure	Time frame
Composition of lower respiratory tract microbiota in patients with different histological types and stages of lung cancer	—

Secondary

Measure	Time frame
• Development of post-operative pneumonia after lung resection for lung cancer • Tumour recurrence und survival	—

Countries

Germany

Contacts

Public ContactMohamed Tarek Badr

Universitätsklinikum Freiburg - Institute for Medical Microbiology and Hygiene

mohamed.tarek.badr@uniklinik-freiburg.de+49 761 270-83685

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026